The Therapeutic Workplace Initiation Study
NCT00249470 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 117
Last updated 2017-12-27
Summary
The primary purpose of the study is to determine if the central feature of the Therapeutic Workplace, the abstinence reinforcement contingency, is critical to initiate cocaine abstinence in injection drug using methadone patients who use cocaine consistently during methadone treatment. All subjects initially will be invited to attend the Therapeutic Workplace for an initial period, but abstinence will not be required to work during that time. During this initial period, vouchers will be contingent only on workplace attendance and performance on the training programs. Subjects (n=70) who attend the workplace consistently during the first 4 weeks of treatment, but who continue to use cocaine will be randomly assigned to a Work Only or an Abstinence Plus Work group. Subjects in the Work Only group will continue to be able to work independent of their urinalysis results. However, subjects in the Abstinence Plus Work group will be required to provide urine samples that show evidence of recent cocaine abstinence. Subjects in both groups will be invited to stay in the workplace for 6 months. We expect the subjects in the Abstinence and Work group will achieve higher rates of abstinence than the subjects in the Work Only group. This result would show that the abstinence reinforcement contingency (i.e., the requirement to provide cocaine-free urine samples to work and earn vouchers) is important in the initiation of abstinence in the study population.
Conditions
- Cocaine-Related Disorders
- Opioid-Related Disorders
- Heroin Dependence
- Substance Abuse, Intravenous
Interventions
- BEHAVIORAL
-
Abstinence & Work
Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
- BEHAVIORAL
-
Work Only
Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH - lead OTHER
Principal Investigators
-
Kenneth Silverman, Ph.D. · Johns Hopkins University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
- Primary Completion
- 2004-05-31
- Completion
- 2004-10-31
Countries
- United States
Study Locations
More Related Trials
-
Acute Withdrawal From Smoked Cocaine - 9
NCT00000292 ·Status: COMPLETED ·Phase: PHASE1
-
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
NCT02444208 ·Status: COMPLETED ·Phase: NA
-
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
NCT00094315 ·Status: UNKNOWN ·Phase: PHASE1
-
Tryptophan and Behavior Therapy for Cocaine Abuse - 1
NCT00000324 ·Status: COMPLETED ·Phase: PHASE2
-
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2
NCT00000316 ·Status: COMPLETED ·Phase: PHASE1
-
Medications for Stopping Cocaine Dependence and Preventing Relapse
NCT00218023 ·Status: COMPLETED ·Phase: PHASE2
-
A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1
NCT00033124 ·Status: UNKNOWN ·Phase: PHASE2
-
Exercise as an Adjunctive Treatment for Cocaine Dependent Patients
NCT01832649 ·Status: COMPLETED ·Phase: NA
-
Recovery Housing and Drug Abuse Treatment Outcome
NCT03278496 ·Status: COMPLETED ·Phase: NA
-
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
NCT00217997 ·Status: COMPLETED
-
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1
NCT00000315 ·Status: COMPLETED ·Phase: PHASE1
-
Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
NCT02111798 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
NCT00713583 ·Status: COMPLETED ·Phase: PHASE2
-
Early Phase II Trials for Cocaine Medication Development - 1
NCT00000317 ·Status: COMPLETED ·Phase: PHASE2
-
Prize Contingency Management for Cocaine-Dependent Methadone Patients
NCT01401270 ·Status: COMPLETED ·Phase: NA
-
Behavioral Incentives to Increase Exercise in Cocaine Dependent Women
NCT01283191 ·Status: COMPLETED ·Phase: NA
-
Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5
NCT00015223 ·Status: COMPLETED ·Phase: PHASE2
-
Cocaine Effects in Humans: Physiology and Behavior - 1
NCT00000200 ·Status: COMPLETED ·Phase: PHASE2
-
Contingency Management for Cocaine Dependence: Cash Versus Vouchers
NCT01366716 ·Status: COMPLETED ·Phase: NA
-
Combined Treatment for Cocaine-Alcohol Dependence - 1
NCT00218569 ·Status: COMPLETED ·Phase: PHASE2
-
Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study
NCT00292136 ·Status: COMPLETED
-
Improving Learning-based Treatment of Cocaine Dependence With Medication
NCT01526538 ·Status: COMPLETED ·Phase: PHASE2
-
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1
NCT00218660 ·Status: COMPLETED ·Phase: PHASE3
-
Dextroamphetamine-Cocaine Behavioral Intervention - 5
NCT00000308 ·Status: COMPLETED ·Phase: PHASE2
-
Agonist Replacement Therapy for Cocaine Dependence
NCT00697138 ·Status: COMPLETED ·Phase: PHASE1